Compare ARDX & REAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARDX | REAL |
|---|---|---|
| Founded | 2007 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Specialty Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.9B |
| IPO Year | 2014 | 2019 |
| Metric | ARDX | REAL |
|---|---|---|
| Price | $6.66 | $12.38 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 8 |
| Target Price | $14.67 | ★ $16.57 |
| AVG Volume (30 Days) | ★ 3.8M | 2.8M |
| Earning Date | 05-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 24.85 |
| EPS | ★ N/A | N/A |
| Revenue | $2,607,000.00 | ★ $600,484,000.00 |
| Revenue This Year | $35.64 | $17.12 |
| Revenue Next Year | $34.12 | $10.88 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 9.32 |
| 52 Week Low | $3.50 | $4.61 |
| 52 Week High | $8.40 | $17.39 |
| Indicator | ARDX | REAL |
|---|---|---|
| Relative Strength Index (RSI) | 46.75 | 44.90 |
| Support Level | $5.47 | $9.61 |
| Resistance Level | $6.69 | $12.84 |
| Average True Range (ATR) | 0.35 | 0.73 |
| MACD | -0.10 | 0.10 |
| Stochastic Oscillator | 58.24 | 65.31 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
The RealReal is the largest pure-play luxury resale platform in the US, generating $1.8 billion in 2024 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 36% of net merchandise value in 2024, which excludes returns, cancellations, and first-party sales.